IP Receptor Antibody (G-7): sc-515509

IP Receptor Antibody (G-7) is a mouse monoclonal IgG1 antibody that detects IP Receptor in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-IP Receptor antibody (G-7) specifically targets IP Receptor, which is a critical component of the prostanoid signaling pathway, primarily binding to prostacyclin (PGI2), a key mediator synthesized in vascular tissues. IP Receptor (G-7) antibody recognizes IP Receptor, which plays a vital role in regulating various physiological processes, including vasodilation and inhibition of platelet aggregation, essential for maintaining cardiovascular health. IP Receptor is predominantly expressed in vascular tissues such as the aorta, lung, and heart, as well as in the kidney and immune tissues, highlighting its significance in both vascular biology and immune responses. Additionally, IP Receptor undergoes post-translational modifications, including glycosylation and phosphorylation, which are essential for proper function and localization within the cell. These modifications can influence receptor activity and interactions with downstream signaling pathways, making IP Receptor a crucial target for therapeutic interventions in conditions like hypertension and cardiovascular diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IP Receptor Antibody (G-7) References:

1. Prostaglandin E receptor EP1 subtype but not prostacyclin IP receptor involved in mucosal blood flow response of mouse stomachs following barrier disruption.  |  Komoike, Y., et al. 2003. Digestion. 67: 186-94. PMID: 12966226
2. Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.  |  Jones, RL., et al. 2006. Br J Pharmacol. 149: 110-20. PMID: 16880763
3. Carbacyclin induces carnitine palmitoyltransferase-1 in cardiomyocytes via peroxisome proliferator-activated receptor (PPAR) delta independent of the IP receptor signaling pathway.  |  Kuroda, T., et al. 2007. J Mol Cell Cardiol. 43: 54-62. PMID: 17540403
4. Involvement of prostaglandin E receptor EP3 subtype and prostacyclin IP receptor in decreased acid response in damaged stomach.  |  Nishio, H., et al. 2007. J Physiol Pharmacol. 58: 407-21. PMID: 17928639
5. 4,5-Dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) is a selective, pseudo-irreversible orthosteric antagonist at the prostacyclin (IP)-receptor expressed by human airway epithelial cells: IP-receptor-mediated inhibition of CXCL9 and CXCL10 release.  |  Ayer, LM., et al. 2008. J Pharmacol Exp Ther. 324: 815-26. PMID: 17962517
6. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.  |  Falcetti, E., et al. 2010. Am J Respir Crit Care Med. 182: 1161-70. PMID: 20622039
7. Novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling.  |  Uchida, T., et al. 2013. J Pharmacol Sci. 123: 392-401. PMID: 24292413
8. Identification of novel IP receptor agonists using historical ligand biased chemical arrays.  |  McKeown, SC., et al. 2014. Bioorg Med Chem Lett. 24: 2247-50. PMID: 24736116
9. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.  |  Kaufmann, P., et al. 2015. Am J Cardiovasc Drugs. 15: 195-203. PMID: 25850750
10. Cloning and expression of a cDNA for the human prostanoid IP receptor.  |  Boie, Y., et al. 1994. J Biol Chem. 269: 12173-8. PMID: 7512962

The preferred IP Receptor antibody is IP Receptor Antibody (B-6): sc-515139.